CDKN2A and cancer: Although frequently observed in various human cancers, the incidence of TP53 mutation (11–30%) is relatively lower in melanoma [58,59], indicating that alterations of other cell cycle regulators, including CDKN2A and its products p14ARF and p16INK4A, are more frequently involved in melanoma tumorigenesis [60].